TMC exited

TMC Innovation Institute leader leaves the organization

Erik Halvorsen has reportedly left his position at the TMC Innovation Institute. Courtesy TMC

Erik Halvorsen, director of the Texas Medical Center's Innovation Institute, has left his position, according to multiple reports.

TMC's medical device innovation team lead, Lance Black, was named as the interim replacement for Halvorsen, according to Xconomy. Black has been with TMC for almost two years.

Neither Halvorsen nor Black could not be reached for comment. This article will be updated as more information becomes available.

Halvorsen has lead the organization since 2015. Before that, he worked in various health technology focused roles in Boston. He oversaw TMC's accelerator program, TMCx. The program graduates around 20 companies per cohort, and there's two cohorts each year — one focused on medical devices, which just concluded with the Nov. 15 Demo Day, and the other, which is about to launch, focused on digital health. TMCx was recently given silver recognition from the Seed Accelerator Rankings Project.

In an interview with InnovationMap earlier this month, Halvorsen talked about his career and Houston's medical innovation ecosystem.

"One of the things that I knew moving to Houston from Boston was that the investment environment for life sciences wasn't as robust as Boston," he said in that interview. "I knew coming in that was going to be a bit of an issue. I also felt like we had the raw materials, that if we ran our program the right way and attracted those companies we needed, the dollars would flow. And that's really been the case."

Trending News

Building Houston

 
 

Houston-based Melax Tech has developed multiple Natural language processing tools that are used by more than 650 health care and life science organizations. Photo via MelaxTech.com

Melax Tech Partners, a leader in natural language technology processing, announced a new partnership with the University of California at Irvine that will help researchers derive insights from the UCI Health Data Science Platform’s electronic health records system and improve patient care.

Melax will implement its signature text annotation tool LANN to pull information from clinical notes, and its CLAMP product to develop natural language processing customizations through the use of AI, according to a statement from the company.

“There has been a strong desire among UCI researchers to have the capability to analyze free-text clinical narrative data using cutting-edge NLP technologies," Kai Zheng, chief research information officer at UCI Health Affairs, says in a statement. "We are delighted to have this opportunity to work with Melax Tech to deploy their AI-driven annotation and analytics tools to help our researchers advance their research agenda by leveraging the vast amount of free-text data that our health system has accumulated in the past two decades.”

Natural language processing, or NLP, allows organizations and healthcare groups to sift through and analyze massive amounts of data at a rapid rate through the use of machine learning and AI. Houston-based Melax Tech, founded in 2017, has developed multiple NLP tools that are used by more than 650 health care and life science organizations, according to its website.

In addition to the recent partnership with UC Irvine, Melax has also recently partnered with Vanderbilt University Medical Center and the University of Western Pennsylvania on similar clinical projects.

Melax has also used its platforms to pull vital information from datasets relating to COVID-19, in both medical and social settings.

In March 2022, it was awarded a Phase 1 NIH Award, valued at $300,000, to develop informatics tools based on COVID-19 datasets with the San Diego Supercomputer Center at UC San Diego. The tool aims to help researchers better understand vast amounts of virus-related data and connect findings with other similar results.

In August, Melax also received another $300,000 grant from the National Institute of Allergy and Infectious Diseases to develop NLP-based algorithms that will "model, extract and synthesize vaccine misinformation from multiple popular social media sources," according to a statement. Melax will also develop a visualization that presents its findings on the misinformation into a compressible format.

"This is a very real topic affecting culture at present," Andre Pontin, CEO at Melax Tech, says in a statement. "And shows that we as a collective business and group of experts continue to be on the cutting-edge of science in the NLP and AI domain."

Trending News